Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scient...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | Neuropsychiatric Disease and Treatment |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-3-month-versus-1-month-f-peer-reviewed-article-NDT |
id |
doaj-2e783d06a91c488f9fb5a86eeb213adf |
---|---|
record_format |
Article |
spelling |
doaj-2e783d06a91c488f9fb5a86eeb213adf2020-11-25T00:03:05ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212019-02-01Volume 1558760244250Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European populationSavitz AJXu HGopal SNuamah IRavenstijn PHough DHargarter LAdam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scientific Affairs, Janssen Cilag EMEA, Neuss, Germany Purpose: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. Patients and methods: In this randomized, DB, parallel-group study, adult patients (18–70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled. The study had 4 phases: screening (3 weeks), open-label (OL) stabilization (17 weeks), DB (48 weeks) and follow-up (4–12 weeks) phase. Patients were treated with fixed-dose PP3M (175–525 mg eq deltoid/gluteal) or PP1M (50–150 mg eq deltoid/gluteal) for 48 weeks in DB phase. Results: In total, 487 European (PP3M, n=242; PP1M, n=245) and 508 non-European patients (PP3M, n=241; PP1M, n=267) entered DB phase (modified intent-to-treat (mITT) [DB] analysis set). Among the 508 non-European patients in mITT set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164). During the DB phase, similar percentage of Europeans (PP3M: 7%; PP1M: 8%) and non-Europeans (PP3M: 9%; PP1M: 10%) experienced relapse (Kaplan–Meier estimate PP3M–PP1M [95% CI] of percentage of relapse-free patients at the end of DB phase [primary endpoint]: European: 1.0% [-4.3%; 6.2%]; non-European: 1.4% [-4.4%; 7.1%]; Asian: 1.6% [-5.7%; 9.0%]; and ROW: 1.4% [-7.0%, 9.8%], per-protocol analysis set). Incidence of treatment-emergent adverse events (TEAEs) was lower in Europeans (PP3M: 56%, PP1M: 59%) than non-Europeans (PP3M: 80%, PP1M: 73%). The most commonly reported TEAE was weight gain. Conclusion: PP3M showed similar efficacy to PP1M in Europeans and non-Europeans, consistent with non-inferiority of PP3M to PP1M observed in overall population. Rates of AEs were higher in non-Europeans. However, weight gain was greater in non-Europeans, especially the Asian population. Keywords: long-acting injectable, non-inferiority, randomized, relapse, tolerabilityhttps://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-3-month-versus-1-month-f-peer-reviewed-article-NDTlong-acting injectablenon-inferiorityrandomizedrelapsetolerability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Savitz AJ Xu H Gopal S Nuamah I Ravenstijn P Hough D Hargarter L |
spellingShingle |
Savitz AJ Xu H Gopal S Nuamah I Ravenstijn P Hough D Hargarter L Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population Neuropsychiatric Disease and Treatment long-acting injectable non-inferiority randomized relapse tolerability |
author_facet |
Savitz AJ Xu H Gopal S Nuamah I Ravenstijn P Hough D Hargarter L |
author_sort |
Savitz AJ |
title |
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population |
title_short |
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population |
title_full |
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population |
title_fullStr |
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population |
title_full_unstemmed |
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population |
title_sort |
efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between european and non-european population |
publisher |
Dove Medical Press |
series |
Neuropsychiatric Disease and Treatment |
issn |
1178-2021 |
publishDate |
2019-02-01 |
description |
Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scientific Affairs, Janssen Cilag EMEA, Neuss, Germany Purpose: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. Patients and methods: In this randomized, DB, parallel-group study, adult patients (18–70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled. The study had 4 phases: screening (3 weeks), open-label (OL) stabilization (17 weeks), DB (48 weeks) and follow-up (4–12 weeks) phase. Patients were treated with fixed-dose PP3M (175–525 mg eq deltoid/gluteal) or PP1M (50–150 mg eq deltoid/gluteal) for 48 weeks in DB phase. Results: In total, 487 European (PP3M, n=242; PP1M, n=245) and 508 non-European patients (PP3M, n=241; PP1M, n=267) entered DB phase (modified intent-to-treat (mITT) [DB] analysis set). Among the 508 non-European patients in mITT set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164). During the DB phase, similar percentage of Europeans (PP3M: 7%; PP1M: 8%) and non-Europeans (PP3M: 9%; PP1M: 10%) experienced relapse (Kaplan–Meier estimate PP3M–PP1M [95% CI] of percentage of relapse-free patients at the end of DB phase [primary endpoint]: European: 1.0% [-4.3%; 6.2%]; non-European: 1.4% [-4.4%; 7.1%]; Asian: 1.6% [-5.7%; 9.0%]; and ROW: 1.4% [-7.0%, 9.8%], per-protocol analysis set). Incidence of treatment-emergent adverse events (TEAEs) was lower in Europeans (PP3M: 56%, PP1M: 59%) than non-Europeans (PP3M: 80%, PP1M: 73%). The most commonly reported TEAE was weight gain. Conclusion: PP3M showed similar efficacy to PP1M in Europeans and non-Europeans, consistent with non-inferiority of PP3M to PP1M observed in overall population. Rates of AEs were higher in non-Europeans. However, weight gain was greater in non-Europeans, especially the Asian population. Keywords: long-acting injectable, non-inferiority, randomized, relapse, tolerability |
topic |
long-acting injectable non-inferiority randomized relapse tolerability |
url |
https://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-3-month-versus-1-month-f-peer-reviewed-article-NDT |
work_keys_str_mv |
AT savitzaj efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT xuh efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT gopals efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT nuamahi efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT ravenstijnp efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT houghd efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation AT hargarterl efficacyandsafetyofpaliperidonepalmitate3monthversus1monthformulationinpatientswithschizophreniacomparisonbetweeneuropeanandnoneuropeanpopulation |
_version_ |
1725435129198804992 |